Document Detail

Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells.
MedLine Citation:
PMID:  19827268     Owner:  NLM     Status:  MEDLINE    
Resveratrol (trans-3,4', 5-trihydroxystilbene) is a naturally occurring polyphenolic compound that has antiinflammatory, antioxidant, neuroprotective properties and acts as a chemopreventive agent. Resveratrol causes cell cycle arrest and induces apoptotic cell death in various types of cancer cells. In the current studies, the effect of resveratrol on phosphoinositide kinase-3 (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway was examined in human U251 glioma cells. Resveratrol decreased both the expression and phosphorylation of Akt. Inhibitors of PI3K (LY294002) and Akt (SH-6) enhanced resveratrol-induced LDH release and caspase-3 activation. Resveratrol reduced phosphorylation of ribosomal protein S6 and the mTOR inhibitor rapamycin further enhanced resveratrol-induced cell death. These results suggest that the downregulation of PI3K/Akt/mTOR signaling pathways may be an important mediator in resveratrol-induced apoptosis in glioma cells.
Hao Jiang; Xia Shang; Hongtao Wu; Subhash C Gautam; Shaza Al-Holou; Christina Li; Jarret Kuo; Lijie Zhang; Michael Chopp
Related Documents :
9165048 - Mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways are not suf...
16428328 - Suppression of the mtor-raptor signaling pathway by the inhibitor of heat shock protein...
16145048 - Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhi...
12176668 - Igf-binding protein-1 inhibits igf effects on adipocyte function: implications for insu...
17341418 - Indomethacin induces apoptosis in 786-o renal cell carcinoma cells by activating mitoge...
6247288 - Adenine nucleotide degradation by the obligate intracellular bacterium rickettsia typhi.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Journal of experimental therapeutics & oncology     Volume:  8     ISSN:  1359-4117     ISO Abbreviation:  J. Exp. Ther. Oncol.     Publication Date:  2009  
Date Detail:
Created Date:  2009-10-15     Completed Date:  2009-10-27     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9604933     Medline TA:  J Exp Ther Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  25-33     Citation Subset:  IM    
Department of Neurology, Henry Ford Hospital, Detroit, Michigan 48202, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Phytogenic / pharmacology*
Caspase 3 / metabolism
Cell Line, Tumor
Cyclin D1 / antagonists & inhibitors
Dose-Response Relationship, Drug
Glioma / drug therapy*,  pathology
Phosphatidylinositol 3-Kinases / antagonists & inhibitors*
Protein Kinases / drug effects*
Proto-Oncogene Proteins c-akt / antagonists & inhibitors*
Signal Transduction / drug effects*
Stilbenes / pharmacology*
TOR Serine-Threonine Kinases
Grant Support
R21 AT003463-01A2/AT/NCCAM NIH HHS; R21 AT003463-01A2/AT/NCCAM NIH HHS
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/CCND1 protein, human; 0/Stilbenes; 136601-57-5/Cyclin D1; EC 2.7.-/Protein Kinases; EC 2.7.1.-/Phosphatidylinositol 3-Kinases; EC protein, human; EC Serine-Threonine Kinases; EC Proteins c-akt; EC 3.4.22.-/Caspase 3; Q369O8926L/resveratrol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
Next Document:  Single fraction spine radiosurgery for myeloma epidural spinal cord compression.